With the same strategy, an ongoing phase I clinical trial is evaluating the pharmacokinetics and pharmacodynamics of exoASO-STAT6 (CDK-004) in advanced HCC, colorectal cancer, and liver metastases from gastric cancer (NCT05375604) (Table 1). Here, STAT6 is linked to hepatocellular carcinoma.